Limited Space Available - Reserve Yours Now!

Exhibit Hall Dates: February 10-12, 2014 | Moscone North Convention Center | San Francisco, CA



Exhibit Hall Features

  • Networking with 3,000+ Colleagues
  • 200+ Exhibiting Companies
  • 34 Interactive Breakout Sessions
  • 170+ Research Posters
  • New Products Showcase
  • Vendor Theater Presentations
  • Networking Reception
  • Plenary Keynote Presentations

Plenary Keynote Presenters

Plenary Keynotes 1 

 Exhibit Hall Agenda-At-A-Glance 

Monday, February 10  
4:30 pm  Registration 
5:00 pm  Plenary Keynote Session  
  Transition from Empiric to Targeted and Personalized Cancer Therapy: Non-small Cell Lung Cancer (NSCLC) as a Model for Addressing Inter- and Intra-Patient Tumor Heterogeneity
David R. Gandara, M.D., Director, Thoracic Oncology Program; Professor and Senior Advisor to Director,UC Davis Cancer Center
6:15 – 7:45 pm  Grand Opening Reception in the Exhibit Hall with Poster Viewing 
Tuesday, February 11  
7:00 am   Registration and Morning Coffee 
8:00 – 9:15 am  Plenary Keynote Session  

Kimberly L. Blackwell, M.D., Professor of Medicine, Assistant Professor of Radiation Oncology; Director, Breast Cancer Program, Duke Cancer Institute 

Discovery of Genetic Basis of Autism and Schizophrenia via Genome Sequencing of Families

C. Thomas Caskey, M.D., FACP, FRSC, Professor, Department of Molecular and Human Genetics,Baylor College of Medicine 

9:15 am – 6:20 pm  Exhibit Hall Open with Poster Viewing 
9:15 – 10:25 am  Refreshment Break 
1:40 – 2:15 pm  Refreshment Break 
4:20 – 5:20 pm  Valentine’s Day Celebration 
5:20 – 6:20 pm  Interactive Breakout Discussions 
Wednesday, February 12  
7:00 am  Registration and Morning Coffee 
8:00 – 9:45 am  Plenary Keynote Panel: Emerging Technologies & Industry Perspectives 

Moderator: Michael H. A. Roehrl, M.D., Ph.D., Director, UHN Program in BioSpecimen Sciences, University of Toronto; Scientist, Ontario Cancer Institute
Panelists: Bernard F. Andruss, Ph.D., Vice President, CDx Development & Regulatory Affairs, Asuragen, Inc.
Rudi Pauwels, Ph.D., Executive Chairman & CEO, Biocartis
Yan Yang, Ph.D., Director, Lab Operations, in vivo Services, The Jackson Laboratory
Jeremy Bridge-Cook, Ph.D., Senior Vice President, Research & Development, Luminex
David C. Duffy, Ph.D., CTO, Quanterix Corporation
Gary Kennedy, CEO, Remedy Informatics

9:45 am – 1:40 pm  Exhibit Hall Open with Poster Viewing 
9:45 – 10:35 am Refreshment Break and Poster Competition Winner Announced 
1:00 – 1:40 pm  Refreshment Break 

  34 Interactive Breakout Discussions 

Choose from interactive breakout discussions across the four Tri-Conference Programs:

  • Real World Coverage and Reimbursement: Implications for Molecular Testing
  • Taking the Cardiac Biomarker ST2 from Discovery to Clinical Adoption
  • How Do Diagnostic Providers Demonstrate Clinical Utility and Cost-Effectiveness?
  • Big Data's Big Role in Understanding Complex Diseases
  • The Future of Prenatal Genomic Testing
  • Extracting Biological Information from WGS/WES
  • Exosomes: Research Trends and Diagnostic Potential
  • The Value Proposition of Digital Pathology
  • Use of Whole Slide Imaging for Primary Diagnosis in Canada
  • Very Fast (Extreme) PCR
  • PCR Quality Control Considerations
  • Biobanking Considerations in Translation Research
  • Biospecimen Considerations in Biomarker-Driven Clinical Trials
  • Sample Prep Challenges for NGS-Based Clinical Assays:
  • The Value of an Integrated Clinical Trials Management System that Facilitates Collaboration Both In and Outside of the Organization
  • Precision Medicine Approaches Applied to Epigenetic Targets
  • Challenges Surrounding Biomarker Discovery for Novel Epigenetic Inhibitors
  • Transcriptomics to Therapeutics: Bridging the lncRNA Divide
  • Overcoming Limitations in Single-Cell Sequencing
  • Clinical-Grade Genomic Interpretation and the Role of Clinical Data Sharing
  • Translational Strategies to Support Combination of Cancer Immunotherapy with Chemotherapy and Radiation
  • Metastatic Tumor Models – Development, Application, and Challenges
  • How to Best Utilize Patient Derived Xenografts in Oncology Drug Development
  • Collaboration, Externalization and Privacy
  • Biological Registration Systems
  • Data Integration Today
  • Translational Informatics
  • Big Data: Should It Be Top-down or Bottom-Up?
  • The Application of Next-Generation Sequencing as a Tool for Translational and Clinical Research
  • Clinical Evaluation of Exosomes as Oncology Biomarkers
  • Are Current CTC Analysis Technologies Ready for Primetime Clinical Use? 
  • Circulating Tumor Cells (CTCs) vs. ctDNA: Which is Best for Liquid Biopsy?
  • Digitizing Traditional PCR Formats

 170+ Scientific Posters 

Navigate the latest peer research at the Tri-Conference Exhibit Hall.
Just some of the posters available for viewing:

  • A Biomarker That Can Predict Which Indication Will Be Approved by the FDA
  • Five years of Whole Slide Imaging(WSI): Successes and Frustrations
  • GenPro: Epigenetic Profiling of CpG DNA Methylation Sites
  • Helper-Dependent Chain Reaction (HDCR), a Unique PCR Method with Sensitivity and Specificity Suitable for DNA Diagnostic Assays
  • High Quality FFPE RNA from Challenging Samples for Digital Multiplex Quantification
  • Isolation and Mutational Analysis of Circulating Tumor Cells from Lung Cancer Patients with Magnetic Sifters and Biochips
  • Methylation, Copy Number, and LOH analysis of Chr8q24 for Discovery of Ovarian and Breast Cancer Biomarkers
  • Pathologist Gaze Pattern in the Evaluation of Specimen Presentation on Digital Platforms
  • Pathway Analysis of Barrett’s Oesophagus Genome Wide Association Study
  • Rapid, Circulating Tumor Cell Detection from Blood Using Microencapsulated System
  • The Genomics Profiling of Lung Cancer Circulating Tumor Cells Enumerated with Spiral Microchannel.
  • Towards the Implementation of a Portable Magnetoresistive Point-of-Care System for Cell-Free DNA Detection in Cancer Diagnosis
  • Utility of ICE COLD-PCR Coupled to Sanger Sequencing or Next Generation Sequencing for Increased Mutation Detection
  • Sensitivity During Patient Monitoring from Circulating Free DNA
  • Whole Exome Sequencing Approach to Identify Genetic Variants Causing Sudden Unexplained Death Syndrome


* Driving in? You can now reserve a parking spot ahead of time! Click here and use promo code tricon2014 to get an additional 5% discount on reserved parking services.

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors

Beckman Coulter Life Sciences 

Boston Healthcare



Charles River no tagline


Cofactor Genonics


Menarini Silicon Biosystems






View All Sponsors